Page 2 - Benevolent Platform News Today

-- Winners to be Announced and Recognised on 11 May at the Prix Galien UK Awards Ceremony in London LONDON, May 2, 2023 /PRNewswire/ -- The Galien Foundation, the premier global institution

Successfully met primary endpoint with BEN-2293 found to be safe and well tolerated Secondary efficacy endpoints, to reduce itch and inflammation, were not achieved. However, initial analyses in... | April 5, 2023

BenevolentAI announces publication of convening notice for AGM London, UK, 24 March 2023: BenevolentAI , a leading, clinical-stageAI-enabled drug discovery and... | March 24, 2023

A year of strong operational progress with focused investment to drive future growth Regulatory News: BenevolentAI ("BenevolentAI" or the "Company" or the "Group") (Euronext Amsterdam: BAI), a

BenevolentAI ??(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate at the upcoming Jefferies London Healthcare Conference from 15-17 November. Nick

London, 6 October 2022: BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, today announces that AstraZeneca, a global, science-led biopharmaceutical company, has selected an additional two novel targets to enter its drug portfolio, for chronic kidney disease (CKD) and id...

Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform Full data expected

Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, announces that during its analyst investor event

BenevolentAI Analyst / Investor Event London, UK, 27 September 2022: BenevolentAI , a... | September 27, 2022

/PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will...